Breakthrough CAR-T Cell Production Method Could Extend Cancer Remission and Advance HIV Cure Research
BRONX, — Scientists from Albert Einstein College of Medicine have unveiled a new technique for producing CAR-T immune cells that may dramatically improve how long these engineered cells remain active in the body, potentially strengthening treatments for blood cancers and bringing researchers closer to long-term HIV control.
The findings, reported in the journal Science Advances, outline a novel approach to manufacturing CAR-T cells that enables them to maintain disease-fighting activity for extended periods compared with conventional CAR-T therapies.
The research was led by Dr. Harris Goldstein, a professor of pediatrics as well as microbiology and immunology at Albert Einstein College of Medicine and director of the Einstein-Rockefeller-CUNY-Mount Sinai Center for AIDS Research.
Goldstein said the team set out to address a major challenge that has limited the long-term effectiveness of CAR-T therapy.
While the treatment can trigger dramatic remissions in patients with blood cancers, the engineered immune cells frequently lose their potency after a period of time, allowing the disease to return.
CAR-T therapy works by extracting T cells from a patient’s immune system and genetically reprogramming them in the laboratory so they can identify and attack specific disease targets such as cancer cells or virus-infected cells.
Once reinfused into the body, these modified cells act as precision-guided immune weapons designed to track down and eliminate harmful cells.
Although this therapy has transformed treatment for certain blood cancers, the gradual loss of CAR-T cell activity remains a major obstacle.
Many patients experience an initial remission, but as the engineered immune cells weaken, cancer can eventually return.
The same challenge has also limited the potential of CAR-T therapy as a treatment strategy for HIV.
Current antiretroviral drugs are highly effective at suppressing HIV replication, but they cannot eliminate the virus hidden in long-lived infected immune cells.
These dormant reservoirs allow the virus to re-emerge if treatment is discontinued, which is why people living with HIV must remain on medication indefinitely.
To tackle this issue, Goldstein’s team designed a new manufacturing method that uses a multi-cytokine fusion protein known as HCW9206.
This engineered molecule combines three naturally occurring immune signaling proteins — IL-7, IL-15 and IL-21 — which are known to enhance T-cell survival and strengthen immune memory.
When the scientists used this fusion protein during CAR-T production, the resulting immune cells showed remarkable improvements in durability and regenerative capacity.
More than half of the CAR-T cells generated using the new approach were identified as T memory stem cells, a rare category of immune cells capable of long-term survival and continuous self-renewal.
By contrast, fewer than five percent of CAR-T cells created using conventional methods possessed these stem-like properties.
In laboratory tests involving mice with human leukemia, both conventional CAR-T cells and the newly engineered cells successfully eliminated cancer cells during initial treatment.
However, when leukemia cells were reintroduced weeks later to mimic disease relapse, only the CAR-T cells produced with the new method responded by expanding again and preventing the cancer from returning.
Similar results were observed in experiments involving HIV infection.
In humanized mouse models, the newly engineered CAR-T cells destroyed significantly more HIV-infected immune cells than standard CAR-T cells.
Researchers also demonstrated that CAR-T cells produced from HIV patients using the new manufacturing technique could successfully eliminate infected cells during laboratory experiments.
The team believes the discovery could influence the future development of CAR-T therapies across multiple diseases.
By creating immune cells capable of persisting for years and continually generating new waves of disease-fighting cells, the technology may help reduce relapse rates in blood cancers and improve long-term survival outcomes.
For HIV research, such durable immune responses could one day allow patients to maintain viral control even after stopping antiretroviral therapy.
If future clinical trials confirm these findings in humans, scientists say the strategy could mark an important step toward achieving sustained drug-free remission and potentially a functional cure for HIV.
-wilayah.com.my
